Monitor upcoming clinical data readouts from both ACAPELLA and IMPACT trials, particularly tumor response and resectability rates, which could serve as key value inflection points. Increased trial size and geographic expansion improve data robustness and potential for future regulatory submissions.
Price Chart
Executive Summary
Alpha Tau Medical announced two clinical trial advancements: the first patient treated in Europe under the ACAPELLA trial for pancreatic cancer and FDA approval to expand its U.S.-based IMPACT trial to include patients on gemcitabine/nab-paclitaxel chemotherapy, increasing total enrollment to 40 patients. These developments mark progress in the company's global clinical strategy for its Alpha DaRT therapy.
Key Facts
- First patient treated in Europe under the ACAPELLA trial for inoperable locally advanced pancreatic cancer (LAPC) at CHU Grenoble Alpes.
- FDA approved an IDE supplement to expand the IMPACT trial in the U.S., Canada, and Israel to include patients receiving gemcitabine/nab-paclitaxel, increasing total enrollment from 30 to 40 patients.
- ACAPELLA trial evaluates Alpha DaRT combined with capecitabine in patients who completed mFOLFIRINOX; IMPACT trial evaluates Alpha DaRT with standard chemotherapy in newly diagnosed unresectable or metastatic pancreatic adenocarcinoma.
- Both trials are multicenter and aim to assess safety, feasibility, tumor response, and potential conversion to surgical resectability.
Financial Impact
No direct financial impact disclosed; trial expansions represent de-risking of clinical development path.
Risk Factors
- Clinical trial results may not meet endpoints or demonstrate sufficient efficacy.
- Regulatory delays or requirements for additional data could impact development timeline.
- Company remains pre-revenue with significant losses and dependence on future funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-046897 |
| Document: ea028745101ex99-2.htm | 0001213900-26-046897 |
| Document: ea0287451-6k_alphatau.htm | 0001213900-26-046897 |
| Document: 0001213900-26-046897-index-headers.html | 0001213900-26-046897 |
| Document: 0001213900-26-046897-index.html | 0001213900-26-046897 |
| Document: 0001213900-26-046897.txt | 0001213900-26-046897 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 17w ago | 6-K | $1.02 $4.00 | ▲ +292.16% | ▲ +289.66% | — |
Jun 1, 2026 17w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +280.14% | — |
May 18, 2026 19w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +275.08% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 7, 2026 21w ago | 6-K | $1.02 $2.58 | ▲ +152.94% | ▲ +149.11% | — |
May 5, 2026 21w ago | 6-K | $1.02 $2.70 | ▲ +164.71% | ▲ +161.97% | — |
May 4, 2026 21w ago | 6-K | $1.02 $2.29 | ▲ +124.51% | ▲ +122.65% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access